-
Jacobio Pharma Retakes Global Rights to SHP2 Inhibitors After Terminating AbbVie Agreement
•
China-based Jacobio Pharma (HKG: 1167) has announced the cancellation of a licensing agreement with US pharmaceutical company AbbVie (NYSE: ABBV), which implies that Jacobio will regain global rights to the out-licensed SHP2 inhibitors. This decision was made as part of an asset portfolio and strategy review. Initially, the deal was…
-
NHSA Unveils Updated National Reimbursement Drug List Rules for 2023
•
The National Healthcare Security Administration (NHSA) has released the updated rules that will govern this year’s National Reimbursement Drug List (NRDL) update. The revisions focus on “Negotiation Drug Renewals” and “Non-exclusive Drug Bidding,” with significant changes to the negotiation drug renewals process, indicating reduced pressure on innovative drugs undergoing renewals.…
-
Binhui Biopharmaceutical and Topgene Biotechnology Partner for New Drug R&D and AI Platform Development
•
Wuhan-based Binhui Biopharmaceutical and Hubei Topgene Biotechnology Co., Ltd have announced a strategic partnership to delve into new drug research and development services, technological innovation, AI platforms, and other collaborative fields. This partnership aims to promote complementary advantages, resource sharing, talent exchange, and establish a joint platform to assist in…
-
Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE
•
The China’s Center for Drug Evaluation (CDE) website has indicated that Huadong Medicine Co., Ltd (SHE: 000963) is moving forward with a priority review for its mirvetuximab soravtansine, an antibody drug conjugate (ADC), for potential use in folate receptor α (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or…
-
NMPA Proposes Revisions to “Drug Inspection Management Measures”, Seeks Public Feedback
•
The National Medical Products Administration (NMPA) has released revised provisions of the “Drug Inspection Management Measures” and is soliciting public feedback on the proposed changes before the deadline of July 10, 2023. The initial “Drug Inspection Management Measures (Trial)” were introduced on May 28, 2021, with the aim of standardizing…
-
Henlius Biotech Suspends IPO on STAR Market, Aims to Optimize Capital Strategy
•
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the suspension of its initial public offering (IPO) to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR), prioritizing capital market planning. The company assures that this decision will not affect its daily operations. Henlius initially planned to dual-list on the STAR…
-
Shanghai’s Huangpu District Launches RMB Fund to Boost Fintech, AI, and Biotech Firms
•
The South China Morning Post reports that the local government in Shanghai’s Huangpu district has established a renminbi-denominated fund to invest in a curated list of 187 fintech, artificial intelligence (AI), and biotech firms. This fund, expected to be operational within the next 12 months, will be managed by an…
